Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Progression 11% Improvement Relative Risk Peng et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 4,020 patients in China No significant difference in progression Peng et al., Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfaa288 Favors HCQ Favors control
Early versus late acute kidney injury among patients with COVID-19—a multicenter study from Wuhan, China
Peng et al., Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfaa288
Peng et al., Early versus late acute kidney injury among patients with COVID-19—a multicenter study from Wuhan, China, Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfaa288
Dec 2020   Source   PDF  
  All Studies   Meta
Retrospective 4020 hospitalized patients in China showing non-statistically significant lower risk of acute kidney injury with HCQ.
risk of progression, 10.8% lower, RR 0.89, p = 0.63, treatment 29 of 453 (6.4%), control 256 of 3,567 (7.2%), NNT 129, CQ/HCQ risk of AKI.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Peng et al., 4 Dec 2020, retrospective, China, peer-reviewed, 21 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: 33. Abadja F, Atemkeng S, Alamartine E et al. Impact of mycophenolic acid and tacrolimus on Th17-related immune response. Transplantation 2011; 92: 396–403 34. Su H, Yang M, Wan C et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int 2020; 98: 219–227 35. Domı́nguez-Gil B, Coll E, Fernández-Ruiz M et al. COVID-19 in Spain: transplantation in the midst of the pandemic. Am J Transplant 2020; 20: 2593–2598 36. Loupy A, Aubert O, Reese P et al. Organ procurement and transplantation during the COVID-19 pandemic. Lancet 2020; 395: e95–e96 Received: 30 June 2020; Editorial decision: 1 October 2020 Early versus late acute kidney injury among patients with COVID-19—a multicenter study from Wuhan, China Suyuan Peng1,2, Huai-Yu Wang1,2, Xiaoyu Sun1, Pengfei Li3, Zhanghui Ye3, Qing Li3, Jinwei Wang4, Xuanyu Shi1, Liu Liu5, Ying Yao5,6, Rui Zeng5, Fan He5, Junhua Li5, Shuwang Ge 5, Xianjun Ke7, Zhibin Zhou7, Erdan Dong8,9,10,11, Haibo Wang12, Gang Xu5, Luxia Zhang1,3,4 and Ming-Hui Zhao4,13 1 National Institute of Health Data Science, Peking University, Beijing, China, 2School of Public Health, Peking University, Beijing, China, Advanced Institute of Information Technology, Peking University, Hangzhou, China, 4Department of Medicine, Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China, 5Department of Nephrology, Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 6Department of Clinical Nutrition, Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 7Taikang Tongji (Wuhan) Hospital, Wuhan, China, 8Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China, 9Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Ministry of Health, Beijing, China, 10Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Beijing, China, 11Beijing Key Laboratory of Cardiovascular Receptors Research, Beijing, China, 12Clinical Trials Unit, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China and 13Peking-Tsinghua Center for Life Sciences, Beijing, China 3 Correspondence to: Luxia Zhang; E-mail:; Gang Xu; E-mail: ABSTRACT Background. Acute kidney injury (AKI) is an important complication of coronavirus disease 2019 (COVID-19), which could be caused by both systematic responses from multi-organ dysfunction and direct virus infection. While advanced evidence is needed regarding its clinical features and mechanisms. We aimed to describe two phenotypes of AKI as well as their risk factors and the association with mortality. Methods. Consecutive hospitalized patients with COVID-19 in tertiary hospitals in Wuhan, China from 1 January 2020 to 23 March 2020 were included. Patients with AKI were classified as AKI-early and AKI-late according to the sequence of organ dysfunction (kidney as the first dysfunctional organ or not). Demographic and clinical features were compared between two AKI groups. Their risk factors and the associations with inhospital mortality were analyzed. Results. A total of 4020 cases with laboratory-confirmed COVID-19 were included and 285 (7.09%) of them were identified as AKI. Compared with patients with AKI-early, patients with AKI-late had significantly higher levels of..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop